Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

3rd-Generation Tyrosine Kinase-Inhibitors and Azacitidine Are Safe and Effective in Myeloid Blast-Phase Chronic Myeloid Leukaemia and Result in a High Proportion of Subjects in 2 nd Chronic Phase Able to Receive a Transplant

Mei Bao, Xiang Wang, Xiao-shuai Zhang, Zong-ru Li, Robert Peter Gale, Xiao-jun Huang, Qian Jiang

Blood (2023) 142 (Supplement 1): 4550.

https://doi.org/10.1182/blood-2023-185346

Published: 2023

Journal Articles

Purine Nucleoside Analogs Plus Rituximab Is an Effective Treatment Choice for Hairy Cell Leukemia-Variant: Results from a Single Center in China

Tingyu Wang, Yi Wang, Ru Li, Ying Yu, Jiawen Chen, Rui Lyu, Wenjie Xiong, Qi Wang, Wei Liu, Wenyang Huang, Weiwei Sui, Gang An, Yan Xu, Dehui Zou, Jianxiang Wang, Lugui Qiu, Shuhua Yi

Blood (2021) 138 (Supplement 1): 3547.

https://doi.org/10.1182/blood-2021-150141

Published: 2021

Journal Articles

Rituximab Maintenance Benefits Less for Follicular Lymphoma Patients with Low Risk of the Follicular Lymphoma International Index

Tingyu Wang, Ru Li, Rui Lv, Ying Yu, Jiawen Chen, Wenjie Xiong, Qi Wang, Wei Liu, Wenyang Huang, Weiwei Sui, Gang An, Yan Xu, Dehui Zou, Jianxiang Wang, Lugui Qiu, Shuhua Yi, Yi Wang

Blood (2021) 138 (Supplement 1): 3544.

https://doi.org/10.1182/blood-2021-147114

Published: 2021

Journal Articles

Safety and Efficacy of GBC/GBM Conditioning Regimen Followed By Autologous Stem Cell Transplantation in Lymphoid Malignancies

Huimin Liu, Wei Liu, Ru Li, Wenyang Huang, Shuhua Yi, MD, Ryu Lv, Shuhui Deng, MD, Gang An, Lugui Qiu, MD, Dehui Zou, MD

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-138774

Published: 2020

Journal Articles

Tyrosine Phosphorylation of Shc Proteins in Normal CD34 + Progenitor Cells and Leukemic Cells

Jie Yang, Biao-Ru Li, Jaya Nayini, Parameswaran Venugopal, Min Tao, Colleen B. Andrews, Harvey D. Preisler

Blood (1999) 94 (1): 373–374.

https://doi.org/10.1182/blood.V94.1.373.413a48b_373_374

Published: 1999

NARROW

3rd-Generation Tyrosine Kinase-Inhibitors and Azacitidine Are Safe and Effective in Myeloid Blast-Phase Chronic Myeloid Leukaemia and Result in a High Proportion of Subjects in 2 nd Chronic Phase Able to Receive a Transplant

Purine Nucleoside Analogs Plus Rituximab Is an Effective Treatment Choice for Hairy Cell Leukemia-Variant: Results from a Single Center in China

Rituximab Maintenance Benefits Less for Follicular Lymphoma Patients with Low Risk of the Follicular Lymphoma International Index

Safety and Efficacy of GBC/GBM Conditioning Regimen Followed By Autologous Stem Cell Transplantation in Lymphoid Malignancies

Tyrosine Phosphorylation of Shc Proteins in Normal CD34 + Progenitor Cells and Leukemic Cells

Email alerts

ASH Publications

American Society of Hematology

3rd-Generation Tyrosine Kinase-Inhibitors and Azacitidine Are Safe and Effective in Myeloid Blast-Phase Chronic Myeloid Leukaemia and Result in a High Proportion of Subjects in 2 nd Chronic Phase Able to Receive a Transplant

Purine Nucleoside Analogs Plus Rituximab Is an Effective Treatment Choice for Hairy Cell Leukemia-Variant: Results from a Single Center in China

Rituximab Maintenance Benefits Less for Follicular Lymphoma Patients with Low Risk of the Follicular Lymphoma International Index

Safety and Efficacy of GBC/GBM Conditioning Regimen Followed By Autologous Stem Cell Transplantation in Lymphoid Malignancies

Tyrosine Phosphorylation of Shc Proteins in Normal CD34 + Progenitor Cells and Leukemic Cells

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only